Bradford S. Hoppe, MD, MPH

Articles by Bradford S. Hoppe, MD, MPH

Radiation Therapy in Diffuse Large B-Cell Lymphoma: A Little Boost Gets You Over the Finish Line

ByOmran Saifi, MD,Bradford S. Hoppe, MD, MPH

December 25th 2022

Bradford S. Hoppe, MD, MPH, and Omran Saifi, MD, offer a peer perspective on research by Gavin Jones, MD, and colleagues into radiation therapy in diffuse large B-cell lymphoma.

ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma

ByKaren M. Winkfield, MD, PhD,Ranjana H. Advani, MD,Leslie K. Ballas, MD,Bouthaina S. Dabaja, MD,Sughosh Dhakal, MD,Christopher R. Flowers, MD, MS,Chul Soo Ha, MD,Bradford S. Hoppe, MD, MPH,David B. Mansur, MD,Nancy P. Mendenhall, MD,Monika L. Metzger, MD,John P. Plastaras, MD, PhD,Kenneth B. Roberts, MD,Ronald Shapiro, MD,Sonali M. Smith, MD,Stephanie A. Terezakis, MD,Anas Younes, MD,Louis S. Constine, MD

December 15th 2016

By combining the most recent medical literature and expert opinion, this revised guideline can aid clinicians in the complex decision-making associated with the management of recurrent Hodgkin lymphoma.

ACR Appropriateness Criteria® Localized Nodal Indolent Lymphoma

ByBradford S. Hoppe, MD, MPH,David C. Hodgson, MD,Ranjana H. Advani, MD,Bouthaina S. Dabaja, MD,Christopher R. Flowers, MD, MS,Chul Soo Ha, MD,Monika L. Metzger, MD,John P. Plastaras, MD, PhD,Kenneth B. Roberts, MD,Ronald Shapiro, MD,Stephanie A. Terezakis, MD,Karen M. Winkfield, MD, PhD,Anas Younes, MD,Louis S. Constine, MD

August 15th 2013

The present guidelines review epidemiology, pathology, presentation, workup, staging, prognostic factors, and treatment options for patients with localized nodal indolent lymphoma, with an emphasis on radiation guidelines, including radiation dose, field design, and radiation techniques.

Improving the Therapeutic Ratio in Hodgkin Lymphoma Through the Use of Proton Therapy

ByBradford S. Hoppe, MD, MPH,Stella Flampouri, PhD,James Lynch, MD,William Slayton, MD,Robert Zaiden, MD,Nancy Price Mendenhall, MD

May 15th 2012

This review addresses the rationale and evidence for-and the challenges, cost implications, and future development of-proton therapy as an important part of the treatment strategy in Hodgkin lymphoma.